QMCO:NASDAQQuantum Corporation Analysis
Data as of 2026-04-27 - not real-time
$7.17
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Quantum Corporation trades at $7.17, comfortably above its 20‑day (≈$6.26) and 50‑day (≈$5.72) moving averages but still below the 200‑day level (≈$7.69), placing it in a neutral technical zone. The RSI sits at 63, indicating modest upward momentum without being overbought, while a bullish MACD histogram (+$0.08) and rising volume suggest short‑term buying pressure. However, the stock faces extreme volatility (≈91% 30‑day) and a high beta (≈3.2), reflecting sensitivity to market swings and a heightened risk profile. Fundamentally, the company posts an 8.6% revenue growth year‑over‑year but remains unprofitable, with a trailing EPS of -$7.71, negative operating cash flow, and a debt load of $137 M against just $13 M of cash. The recent partnership with Pink Elephant to deliver sovereign, low‑cost data resilience services in Europe could serve as a catalyst for top‑line expansion, yet the balance sheet weakness and negative margins temper optimism.
Given the current price near the resistance level (~$7.66) and the “Extreme Greed” market sentiment, the stock may attract speculative interest, but investors should weigh the upside potential against the substantial downside risk stemming from cash‑burn, leverage, and sector volatility.
Given the current price near the resistance level (~$7.66) and the “Extreme Greed” market sentiment, the stock may attract speculative interest, but investors should weigh the upside potential against the substantial downside risk stemming from cash‑burn, leverage, and sector volatility.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bullish MACD and rising volume support near‑term stability
- High volatility and beta increase short‑term price swings
- Negative earnings and cash flow limit upside
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- Revenue growth of 8.6% and low price‑to‑sales ratio suggest upside
- Strategic partnership with Pink Elephant could open new markets
- Current valuation discounts the company relative to peers
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Sustained operating losses and high debt burden
- Continued cash burn and negative free cash flow
- Sector competition and rapid technology shifts risk long‑term viability
Key Metrics & Analysis
Financial Health
Revenue Growth8.60%
Profit Margin-37.76%
P/E Ratio-8.3
ROA-9.94%
P/B Ratio-0.6
Op. Cash Flow$-40706000
Free Cash Flow$-38030376
Industry P/E38.1
Technical Analysis
TrendNeutral
RSI63.2
Support$4.19
Resistance$7.66
MA 20$6.26
MA 50$5.72
MA 200$7.69
MACDBullish
VolumeIncreasing
Fear & Greed Index88.02
Valuation
Target Price$10.50
Upside/Downside46.44%
GradeUndervalued
TypeBlend
Risk Assessment
Beta3.20
Volatility90.90%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.